GH, IGF-I and binding proteins in altered nutritional states

International Journal of Obesity

Volumn 24, Issue SUPPL. 2, 2000, Pages

  Ross, R J M ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cirrhosis; Fasting; GH resistance; Growth hormone; IGF binding protein; IGF I

Indexed keywords

GROWTH HORMONE; GROWTH PROMOTOR; SOMATOMEDIN C;

ADULT; ANOREXIA; CATABOLISM; CHRONIC LIVER DISEASE; CONFERENCE PAPER; CRITICAL ILLNESS; DIABETES MELLITUS; DIET RESTRICTION; DRUG ABUSE; HUMAN; NITROGEN BALANCE; NUTRITIONAL STATUS; OBESITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SEPSIS;

CHRONIC DISEASE; CRITICAL ILLNESS; FASTING; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIVER DISEASES; NUTRITIONAL STATUS; POSTOPERATIVE PERIOD; SEPSIS;

EID: 0033928293     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj/ijo/0801288     Document Type: Conference Paper

References (25)

1. Isley WL, Underwood LE, Clemmons DR. Dietary components that tegulate serum somatomedin-C concentrations in humans. J Clin Invest 1983; 71: 175-182.
2. Ho KY, Veldhuis JD, Johnson ML et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Endocr Metab 1988; 81: 968-975.
3. Hartmann ML, Veldhuis JD, Johnson ML et al. Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. J Clin Endocr Metab 1992; 74: 757-765.
4. Cotterill AM, Holly JM, Wass JA. The regulation of insulin-like growth factor binding protein (IGFBP)-1 during prolonged fasting. Clin Endocrinol 1993; 30: 357-362.
5. Cuneo RC, Hickman PB, Wallace JD et al. Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease. Clin Endocr 1995; 43: 265-75 (Abstract).
6. Donaghy A, Ross RIM, Gimson A, Hughes SC, Holly J, Williams R. Growth hormone, Insulin-like growth factor-1 and insulin-like growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology 1995; 21: 680-688.
7. Chang T, Lin J, Yu S. Absence of growth-hormone receptor in hepatocellular carcinoma and cirrhotic liver. Hepatology 1990; 11: 123-126.
8. Shen XY, Holt RIG, Miell JP et al. Cirrhotic liver expresses low levels of the full length and truncated growth hormone receptor. J Clin Endocr Metab 1998; 83: 2532-2538.
9. Ross RIM, Chew SL, D'Souza LL et al. IGF-1 and IGF binding protein genes in normal liver and cirrhosis. J Endocr 1996; 83: 209-216.
10. Ross RJM, Rodriguez-Arnao J, Donaghy A et al. Expression of IGFBP-1 in normal and cirrhotic human livers. J Endocr 1994; 141: 377-382.
11. Donaghy A, Ross RIM, Wicks C et al. Growth hormone therapy in cirrhosis: a double blind, placebo controlled, pilot study of efficacy and safety. Gastroenterology 1997; 113: 1617-16622 (Abstract).
12. Cotterill AM, Mendel P, Holly JMP et al. The differential regulation of the circulating levels of the insulin-like growth factor binding proteins (IGFBP) 1,2 and 3 after elective abdominal surgery. Clin Endocr 1996; 44: 99-101.
13. Cuthbertson DP. Observations on the disturbance of metabolism produced by injury to the limbs. QJM 1931: 233-246.
14. Miell JP, Taylor AM, Jones J et al. Administration of human recombinant insulin-like growth factor-1 to patients following major gastrointestinal surgery. Clin Endocr 1992; 37: 542-551.
15. Van den Berghe G, De Zegher F, Bouillon R. Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocr Metab 1998; 83: 1827-1834.
16. Ross RIM, Miell J, Freeman E et al. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin like growth factor-1. Clin Endocr 1991; 35: 47-54.
17. Van den Berghe G, De Zegher F, Lauwers P, Veldhuis JD. Growth hormone secretion in critical illness: effect of dopamine. J Clin Endocr Metab 1994; 79: 1141-1146.
18. Voerman HJ, Strack van Schijndel RJM, Groeneveld ABJ, De Boer H, Nauta JP, Thijs LG. Pulsatile hormone secretion during severe sepsis: accuracy of different blood sampling regimens. Metabolism 1992; 9: 934-940.
19. Hawker FH, Stewart PM, Baxter RC et al. Relationship of somatomedin-C/insulin-like growth factor I levels to conventional nutritional indices in critically ill patients. Crit Care Med 1987; 15: 732-736.
20. Davies SC, Wass JAH, Ross RJM et al. The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. J Endocr 1991; 30: 469-473.
21. Timmins AC, Cotterill AM, Cwyfan-Hughes SC et al. Critical illness is associated with low levels of insulin like growth factor-1 (IGF-I) and IGE-II, alterations in IGF binding proteins (IGFBP) and induction of an IGFBP-3 protease. Crit Care Med 1996; 24: 1460-1466.
22. Yarwood GD, Ross RJM, Medbak S, Coakley J, Hinds CJ. Administration of human recombinant insulin like growth factor-1 to critically ill patients on the intensive care unit. Crit Care Med 1997; 25: 1352-91361.
23. Jenkins RC, Ross RJM. Growth hormone therapy for protein catabolism. Q J Med 1996; 89: 813-819.
24. Balteskard L, Unneberg K, Mjaaland M, Sager G, Jenssen TG, Revhaug A. Treatment with growth hormone and insulin-like growth factor-1 in septicemia: effects on carbohydrate metabolism. Eur Surg Res 1998; 30: 79-94.
25. Liao W, Rudling M, Angelin B. Growth hormone potentiates the in vivo biological activities of endotoxin in the rat. Eur J Clin Invest 1996; 26: 254-258.